Skip to main content

Peer Review reports

From: Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

Original Submission
25 Jun 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
1 Sep 2022 Reviewed Reviewer Report
8 Dec 2022 Reviewed Reviewer Report
29 Jan 2023 Reviewed Reviewer Report
1 Mar 2023 Author responded Author comments - Yazed AlRuthia
Resubmission - Version 3
1 Mar 2023 Submitted Manuscript version 3
7 Mar 2023 Author responded Author comments - Yazed AlRuthia
Resubmission - Version 4
7 Mar 2023 Submitted Manuscript version 4
15 Mar 2023 Author responded Author comments - Yazed AlRuthia
Resubmission - Version 5
15 Mar 2023 Submitted Manuscript version 5
18 Mar 2023 Author responded Author comments - Yazed AlRuthia
Resubmission - Version 6
18 Mar 2023 Submitted Manuscript version 6
3 Apr 2023 Reviewed Reviewer Report
4 Apr 2023 Reviewed Reviewer Report
8 Apr 2023 Reviewed Reviewer Report
15 Apr 2023 Author responded Author comments - Yazed AlRuthia
Resubmission - Version 7
15 Apr 2023 Submitted Manuscript version 7
25 Apr 2023 Author responded Author comments - Yazed AlRuthia
Resubmission - Version 8
25 Apr 2023 Submitted Manuscript version 8
Publishing
27 Apr 2023 Editorially accepted
26 May 2023 Article published 10.1186/s12913-023-09462-z

You can find further information about peer review here.

Back to article page